source
- AstraZeneca and Amgen’s Tezspire shows positive results in Phase 3 eosinophilic esophagitis trialAstraZeneca and Amgen continue to co‑develop and co‑commercialize Tezspire, an anti‑inflammatory therapy already approved for asthma and chronic rhinosinusitis. The partners are preparing another F…
- CEPI pledges up to $16.5M to advance Egyptian biotech's Ebola vaccine candidateCEPI has committed up to $16.5 million to help bring Minapharm’s Bundibugyo Ebola vaccine candidate into clinical testing. The funding will support preclinical work and an early-stage human trial…